Protara Therapeutics Inc. (TARA), a clinical-stage biopharmaceutical company, has a clinical trial catalyst to watch next quarter related to its investigational cell therapy, TARA-002.
TARA-002, which is derived from an inactivated Group A Streptococcus pyogenes bacterium, specifically type 3, strain SU, is being developed for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com